OBJECTIVE To develop paclitaxel polymeric micelle(PTX PM and albumin-paclitaxel polymeric micelle（HSA-PTX PM，to evaluate the anti-tumor activity of two formulations and the PTX injection sold in market. METHODS The particle size and morphology of PTX PM and HSA-PTX PM were analyzed by ZetePALS Zeta Potential Analyzer and Transmission Electron Microscope. The anti-tumor activity was determined by traditional method and in vivo imaging technique method. The effect of two formulations on life span of B16 tumor-bearing mice was investigated by the B16 tumor-bearing mouse model . RESULTS The size distributions of PTX PM and HSA-PTX PM were similar. The effective diameters of two formulations were both around 100 nm. The appearance of the particle was spherical. In vivo imaging pictures showed HSA-PTX PM and PTX PM obtained better anti-tumor effect than the PTX injection and HSA-PTX PM was best. HSA-PTX PM with the inhibition rate of 72.92% was better than PTX PM（66.49%and PTX injection（47.68%（P<0.05.The results were similar to the traditional method. HSA-PTX PM prolonged the mean life span of B16 tumor-bearing mouse compared with PTX injection. CONCLUSION The anti-tumor activities of PTX PM and HSA-PTX PM was better than PTX injection while HSA-PTX PM was the best. The technology using the drug carrier albumin together with polymeric micelle has a wonderful prospect.
SUN Min-min;HO Yn-li;TI Wen;LIU Nn;M Ming-shu;YIN Zhe;NIE Shng-hi;ZHNG Xio-ning.
Anti-tumor Effect of Albumin-Paclitaxel Polymeric Micelle[J]. Chinese Pharmaceutical Journal, 2011, 46(3): 199-202
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] JONES M C， GAO H， LEROUX J C. Reverse polymeric micelles for pharmaceutical applications [J]. J Controlled Release， 2008， 132（3： 208-215. [2] HUH K M， LEE S C， CHO Y W， et al. Hydrotropic polymer micelle system for delivery of paclitaxel [J]. J Controlled Release， 2005， 101（1-3：59-68. [3] DESAI N， TRIEU V， YAO Z， et al. Increased antitumor activity， intratumor paclitaxel concentrations， and endothelial cell transport of Cremophor-free， albumin-bound paclitaxel， ABI-007， compared with Cremophor-based paclitaxel [J]. Clin Cancer Res， 2006， 12（4： 1317-1324. [4] HAWKINS M J， SOON-SHIONG P， DESAI N. Protein nanoparticles as drug carriers in clinical medicine [J]. Adv Drug Deliv Rev， 2008， 60（8： 876-885. [5] SOMA D， KITAYAMA J， ISHIGAMI H， et al. Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration [J]. J Surg Res， 2009， 155（1： 142-146. [6] ZHANG X C， JACKSON J K， WONG W， et al. Development of biodegradable polymeric paste formulations for taxol： an in vitro and in vivo study [J]. Inter J Pharm， 1996， 137（2： 199-208. [7] CHEN J， CORBIN I R， LI H， et al. Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo [J]. J Am Chem Soc， 2007， 129(18：5798-5799. [8] NOTTING I C， BUIJS J T， QUR I， et al. Whole body bioluminescent imaging of human uveal melanoma in a new mouse model of local tumor growth and metastasis [J]. Invest Ophthalmol Vis Sci， 2005， 46（5： 1581-1587. [9] REN Y R， CHEN J， LIU H Y， et al. The study of the tumorigenicity and metastasis ability in human lung cancer cell line L9981 [J]. Chin J Lung Cancer(中国肺癌杂志， 2008， 11（3： 321-326. [10] ZOU J， SUN H. Apoptosis induced by controlled release paclitaxel nanoparticles in mouse-borne breast cancer [J].Chin Cancer Clin(中国肿瘤临床， 2004，34(7：407-410. [11] MAEDA H， WU J， SAWA T. Tumor vascular permeability and the EPR effect in macromolecular therapeutics：a review [J]. J Controlled Release， 2000， 65（1-2：271-284.
PDF(1321 KB)
